海正药业(600267.SH):参与全国药品集采 琥珀酸索利那新片拟中标
格隆汇1月17日丨海正药业(600267.SH)公布,2020年1月17日,公司参加了联合采购办公室(“联采办”)组织的第二批全国药品集中采购的投标工作。公司根据《国家食品药品监督管理总局关于发布化学药品注册分类改革工作方案的公告》〔2016 年第51 号〕,按化学药品新注册分类批准的仿制药品琥珀酸索利那新片拟中标本次集中采购,并且公司根据各省市场潜力进行了省份遴选。
拟中标产品基本情况如下:

公司于2019年7月获得国家药品监督管理局核准签发的琥珀酸索利那新片的《药品注册批件》,截至目前该品种尚未实现销售。经查询IMS数据库,琥珀酸索利那新片2018年和2019年1-9月在中国的销售额分别为583.42万美元、464.52万美元。
此次药品集中采购是国家组织在2020年1月开展的第二批国家药品集中采购,在执行上要求全国医疗机构优先使用集中采购中选品种,并确保完成约定采购量。公司此次拟中选的品种为公司根据《国家食品药品监督管理总局关于发布化学药品注册分类改革工作方案的公告》〔2016 年第51 号〕,按化学药品新注册分类批准的仿制药品,若确定中选、签订购销合同并实施后,将有利于上述产品快速打开国内销售市场,提高市场占有率,促进公司制剂业务的进一步发展,提升公司的品牌影响力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.